Clinical advances in epigenetic therapies for lymphoma

Clinical Epigenetics

Table 1 Summary of key epigenetic therapies by lymphoma type

Lymphoma type	Epigenetic inhibitor class	Key result
Lymphoma type	Epigenetic inhibitor class	Monotherapy	Combination therapy
BCL	DMNT	No clinical benefit [31]	R/R DLBCL (azacitidine + vorinostat + gemcitabine/busulfan/melphalan): ORR 78% [32]
	EZH2	MT EZH2 FL (tazemetostat): ORR 69% [33]	Data not yet available
	PMNT	Data not yet available	No studies
	HDAC	R/R DLBCL (fimepinostat): ORR 37% FL (vorinostat): ORR 47–49% [34, 35]	NHL (vorinostat + R-CVEP): ORR 41–57% [36, 37]
TCL	EZH2	TCL (valemetostat): ORR 80% [38]	No studies
TCL	HDAC	CTCL (vorinostat): ORR 30% [39] CTCL (romidepsin): ORR 33–41% [100,101,102] PTCL (romidepsin): ORR 25% [40]	R/R PTCL (romidepsin + pralatrexate): ORR 71% [41]
HL	HDAC	Ineffective vs immunomodulating agents [42]	Vorinostat + mTOR inhibitor: ORR 33–55% [43]
HL	DMNT	No studies	Azacitidine + vorinostat + chemotherapy (gemcitabine/busulfan/melphalan): ORR 88% [32]

BCL B cell lymphoma; CTCL cutaneous T cell lymphoma; DLBCL diffuse large B cell lymphoma; EZH2 enhancer of zeste homolog 2; DMNT DNA N-methyltransferase; FL follicular lymphoma; HDAC histone deacetylase; HL Hodgkin lymphoma; mTOR mechanistic target of rapamycin; NHL non-Hodgkin lymphoma; ORR objective response rate; PMNT phenylethanolamine N-methyltransferase; PTCL peripheral T cell lymphoma; R-CVEP rituximab, cyclophosphamide, vorinostat, etoposide, and prednisone; R/R relapsed or refractory; and TCL T cell lymphoma

ISSN: 1868-7083